Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Clinical Microbiology & Infectious Diseases
Published in: European Journal of Clinical Microbiology & Infectious Diseases 5/2014

01-05-2014 | Review

Candida glabrata: a review of its features and resistance

Authors: C. F. Rodrigues, S. Silva, M. Henriques

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 5/2014

Login to get access

Abstract

Candida species belong to the normal microbiota of the oral cavity and gastrointestinal and vaginal tracts, and are responsible for several clinical manifestations, from mucocutaneous overgrowth to bloodstream infections. Once believed to be non-pathogenic, Candida glabrata was rapidly blamable for many human diseases. Year after year, these pathological circumstances are more recurrent and problematic to treat, especially when patients reveal any level of immunosuppression. These difficulties arise from the capacity of C. glabrata to form biofilms and also from its high resistance to traditional antifungal therapies. Thus, this review intends to present an excerpt of the biology, epidemiology, and pathology of C. glabrata, and detail an approach to its resistance mechanisms based on studies carried out up to the present.
Literature
1.
Lass-Flörl C (2009) The changing face of epidemiology of invasive fungal disease in Europe. Mycoses 52:197–205PubMed
2.
Silva S, Negri M, Henriques M, Oliveira R, Williams DW, Azeredo J (2012) Candida glabrata, Candida parapsilosis and Candida tropicalis: biology, epidemiology, pathogenicity and antifungal resistance. FEMS Microbiol Rev 36(2):288–305. doi:10.​1111/​j.​1574-6976.​2011.​00278.​x PubMed
3.
Odds FC (1988) Candida and candidosis, 2nd edn. Bailliere Tindall, London, UK
4.
Calderone RA (2002) Introduction and historical perspectives. In: Calderone RA (ed) Candida and candidiasis. ASM Press, Washington D.C., pp 15–25
5.
Pfaller MA, Diekema DJ (2007) Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20:133–163PubMedCentralPubMed
6.
Bassetti M, Righi E, Costa A et al (2006) Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis 6:21PubMedCentralPubMed
7.
Colombo AL, Guimarães T, Silva LR et al (2007) Prospective observational study of candidemia in São Paulo, Brazil: incidence rate, epidemiology, and predictors of mortality. Infect Control Hosp Epidemiol 28:570–576PubMed
8.
Chakrabarti A, Chatterjee SS, Rao KLN et al (2009) Recent experience with fungaemia: change in species distribution and azole resistance. Scand J Infect Dis 41:275–284PubMed
9.
Hasan F, Xess I, Wang X, Jain N, Fries BC (2009) Biofilm formation in clinical Candida isolates and its association with virulence. Microbes Infect 11:753–761PubMedCentralPubMed
10.
Krcmery V (1999) Torulopsis glabrata: an emerging yeast pathogen in cancer patients. Int J Antimicrob Agents 11:1–6PubMed
11.
Krcmery V, Barnes AJ (2002) Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. J Hosp Infect 50:243–260PubMed
12.
Kaur R, Domergue R, Zupancic ML, Cormack BP (2005) A yeast by any other name: Candida glabrata and its interaction with the host. Curr Opin Microbiol 8:378–384PubMed
13.
Pfaller MA, Diekema DJ (2004) Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin Microbiol Infect 10(Suppl 1):11–23PubMed
14.
Bethea EK, Carver BJ, Montedonico AE, Reynolds TB (2010) The inositol regulon controls viability in Candida glabrata. Microbiology 156:452–462PubMedCentralPubMed
15.
Sardi JCO, Scorzoni L, Bernardi T, Fusco-Almeida AM, Mendes Giannini MJS (2013) Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. J Med Microbiol 62:10–24PubMed
16.
Kim J, Sudbery P (2011) Candida albicans, a major human fungal pathogen. J Microbiol 49:171–177PubMed
17.
Lim CS, Rosli R, Seow HF, Chong PP (2012) Candida and invasive candidiasis: back to basics. Eur J Clin Microbiol Infect Dis 31:21–31PubMed
18.
Vincent JL, Rello J, Marshall J et al (2009) International study of the prevalence and outcomes of infection in intensive care units. JAMA 302:2323–2329PubMed
19.
Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB (2006) Inflammatory response and clinical course of adult patients with nosocomial bloodstream infections caused by Candida spp. Clin Microbiol Infect 12:170–177PubMed
20.
Vazquez JA, Dembry LM, Sanchez V et al (1998) Nosocomial Candida glabrata colonization: an epidemiologic study. J Clin Microbiol 36:421–426PubMedCentralPubMed
21.
Vazquez JA, Sanchez V, Dmuchowski C, Dembry LM, Sobel JD, Zervos MJ (1993) Nosocomial acquisition of Candida albicans: an epidemiologic study. J Infect Dis 168:195–201PubMed
22.
Reagan DR, Pfaller MA, Hollis RJ, Wenzel RP (1990) Characterization of the sequence of colonization and nosocomial candidemia using DNA fingerprinting and a DNA probe. J Clin Microbiol 28:2733–2738PubMedCentralPubMed
23.
Hagerty JA, Ortiz J, Reich D, Manzarbeitia C (2003) Fungal infections in solid organ transplant patients. Surg Infect (Larchmt) 4:263–271
24.
25.
Samaranayake LP, Fidel PL, Naglik JR et al (2002) Fungal infections associated with HIV infection. Oral Dis 8:151–160PubMed
26.
Rajendran R, Robertson DP, Hodge PJ, Lappin DF, Ramage G (2010) Hydrolytic enzyme production is associated with Candida albicans biofilm formation from patients with type 1 diabetes. Mycopathologia 170:229–235PubMed
27.
Kuhn DM, Ghannoum MA (2004) Candida biofilms: antifungal resistance and emerging therapeutic options. Curr Opin Investig Drugs 5:186–197PubMed
28.
de Almeida AA, Mesquita CS, Svidzinski TI, de Oliveira KM (2013) Antifungal susceptibility and distribution of Candida spp. isolates from the University Hospital in the municipality of Dourados, State of Mato Grosso do Sul, Brazil. Rev Soc Bras Med Trop 46(3):335–339. doi:10.​1590/​0037-8682-0074-2012 PubMed
29.
Fidel PL Jr, Vazquez JA, Sobel JD (1999) Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin Microbiol Rev 12:80–96PubMedCentralPubMed
30.
Dujon B, Sherman D, Fischer G et al (2004) Genome evolution in yeasts. Nature 430:35–44PubMed
31.
Wolfe KH, Shields DC (1997) Molecular evidence for an ancient duplication of the entire yeast genome. Nature 387:708–713PubMed
32.
Butler G, Rasmussen MD, Lin MF et al (2009) Evolution of pathogenicity and sexual reproduction in eight Candida genomes. Nature 459:657–662PubMedCentralPubMed
33.
Brunke S, Hube B (2013) Two unlike cousins: Candida albicans and C. glabrata infection strategies. Cell Microbiol 15(5):701–708PubMedCentralPubMed
34.
35.
Butler G, Kenny C, Fagan A, Kurischko C, Gaillardin C, Wolfe KH (2004) Evolution of the MAT locus and its Ho endonuclease in yeast species. Proc Natl Acad Sci U S A 101:1632–1637PubMedCentralPubMed
36.
Hittinger CT, Rokas A, Carroll SB (2004) Parallel inactivation of multiple GAL pathway genes and ecological diversification in yeasts. Proc Natl Acad Sci U S A 101:14144–14149PubMedCentralPubMed
37.
Roetzer A, Gabaldón T, Schüller C (2011) From Saccharomyces cerevisiae to Candida glabrata in a few easy steps: important adaptations for an opportunistic pathogen. FEMS Microbiol Lett 314:1–9PubMedCentralPubMed
38.
Kramer A, Schwebke I, Kampf G (2006) How long do nosocomial pathogens persist on inanimate surfaces? A systematic review. BMC Infect Dis 6:130PubMedCentralPubMed
39.
Cox GM, Harrison TS, Mcdade HC et al (2003) Superoxide dismutase influences the virulence of Cryptococcus neoformans by affecting growth within macrophages. Infect Immun 71(1):173–180PubMedCentralPubMed
40.
Nicola AM, Casadevall A, Goldman DL (2008) Fungal killing by mammalian phagocytic cells. Curr Opin Microbiol 11(4):313–317PubMedCentralPubMed
41.
42.
Nakagawa Y, Kanbe T, Mizuguchi I (2003) Disruption of the human pathogenic yeast Candida albicans catalase gene decreases survival in mouse-model infection and elevates susceptibility to higher temperature and to detergents. Microbiol Immunol 47(6):395–403PubMed
43.
Roetzer A, Gratz N, Kovarik P, Schüller C (2010) Autophagy supports Candida glabrata survival during phagocytosis. Cell Microbiol 12(2):199–216PubMedCentralPubMed
44.
Saijo T, Miyazaki T, Izumikawa K et al (2010) Skn7p is involved in oxidative stress response and virulence of Candida glabrata. Mycopathologia 169(2):81–90PubMed
45.
Lee J, Godon C, Lagniel G et al (1999) Yap1 and Skn7 control two specialized oxidative stress response regulons in yeast. J Biol Chem 274(23):16040–16046PubMed
46.
Gulshan K, Lee SS, Moye-Rowley WS (2011) Differential oxidant tolerance determined by the key transcription factor Yap1 is controlled by levels of the Yap1-binding protein, Ybp1. J Biol Chem 286(39):34071–34081PubMedCentralPubMed
47.
Roetzer A, Klopf E, Gratz N et al (2011) Regulation of Candida glabrata oxidative stress resistance is adapted to host environment. FEBS Lett 585(2):319–327PubMedCentralPubMed
48.
Kaur R, Ma B, Cormack BP (2007) A family of glycosylphosphatidylinositol-linked aspartyl proteases is required for virulence of Candida glabrata. Proc Natl Acad Sci U S A 104(18):7628–7633PubMedCentralPubMed
49.
Lorenz MC, Bender JA, Fink GR (2004) Transcriptional response of Candida albicans upon internalization by macrophages. Eukaryot Cell 3(5):1076–1087PubMedCentralPubMed
50.
Roetzer A, Gregori C, Jennings AM et al (2008) Candida glabrata environmental stress response involves Saccharomyces cerevisiae Msn2/4 orthologous transcription factors. Mol Microbiol 69(3):603–620PubMedCentralPubMed
51.
Seider K, Brunke S, Schild L et al (2011) The facultative intracellular pathogen Candida glabrata subverts macrophage cytokine production and phagolysosome maturation. J Immunol 187(6):3072–3086PubMed
52.
Klionsky DJ (2004) Cell biology: regulated self-cannibalism. Nature 431(7004):31–32PubMed
53.
54.
Xie Z, Klionsky DJ (2007) Autophagosome formation: core machinery and adaptations. Nat Cell Biol 9(10):1102–1109PubMed
55.
Verstrepen KJ, Jansen A, Lewitter F, Fink GR (2005) Intragenic tandem repeats generate functional variability. Nat Genet 37(9):986–990PubMedCentralPubMed
56.
Sundstrom P (2002) Adhesion in Candida spp. Cell Microbiol 4(8):461–469PubMed
57.
Ruan SY, Hsueh PR (2009) Invasive candidiasis: an overview from Taiwan. J Formos Med Assoc 108(6):443–451PubMed
58.
Kraneveld EA, De Soet JJ, Deng DM et al (2011) Identification and differential gene expression of adhesin-like wall proteins in Candida glabrata biofilms. Mycopathologia 172:415–427. doi:10.​1007/​ s11046-011-9446-2 PubMed
59.
De Groot PW, Kraneveld EA, Yin QY et al (2008) The cell wall of the human pathogen Candida glabrata: differential incorporation of novel adhesin-like wall proteins. Eukaryot Cell 7(11):1951–1964PubMedCentralPubMed
60.
Domergue R, Castaño I, De Las Peñas A et al (2005) Nicotinic acid limitation regulates silencing of Candida adhesins during UTI. Science 308(5723):866–870PubMed
61.
Castaño I, Pan SJ, Zupancic M, Hennequin C, Dujon B, Cormack BP (2005) Telomere length control and transcriptional regulation of subtelomeric adhesins in Candida glabrata. Mol Microbiol 55(4):1246–1258PubMed
62.
Jandric Z, Schüller C (2011) Stress response in Candida glabrata: pieces of a fragmented picture. Future Microbiol 6(12):1475–1484PubMed
63.
64.
Jayatilake JA, Samaranayake YH, Cheung LK, Samaranayake LP (2006) Quantitative evaluation of tissue invasion by wild type, hyphal and SAP mutants of Candida albicans, and non-albicans Candida species in reconstituted human oral epithelium. J Oral Pathol Med 35(8):484–491PubMed
65.
Tamura NK, Negri MF, Bonassoli LA, Svidzinski TI (2007) Virulence factors for Candida spp recovered from intravascular catheters and hospital workers hands. Rev Soc Bras Med Trop 40:91–93PubMed
66.
Silva S, Henriques M, Martins A, Oliveira R, Williams D, Azeredo J (2009) Biofilms of non-Candida albicans Candida species: quantification, structure and matrix composition. Med Mycol 47:681–689PubMed
67.
Iraqui I, Garcia-Sanchez S, Aubert S et al (2005) The Yak1p kinase controls expression of adhesins and biofilm formation in Candida glabrata in a Sir4p-dependent pathway. Mol Microbiol 55:1259–1271PubMed
68.
De Las Peñas A, Pan SJ, Castaño I, Alder J, Cregg R, Cormack BP (2003) Virulence-related surface glycoproteins in the yeast pathogen Candida glabrata are encoded in subtelomeric clusters and subject to RAP1- and SIR-dependent transcriptional silencing. Genes Dev 17:2245–2258
69.
Cormack BP, Ghori N, Falkow S (1999) An adhesin of the yeast pathogen Candida glabrata mediating adherence to human epithelial cells. Science 285:578–582PubMed
70.
71.
van Dyk D, Pretorius IS, Bauer FF (2005) Mss11p is a central element of the regulatory network that controls FLO11 expression and invasive growth in Saccharomyces cerevisiae. Genetics 169:91–106PubMedCentralPubMed
72.
Riera M, Mogensen E, d’Enfert C, Janbon G (2012) New regulators of biofilm development in Candida glabrata. Res Microbiol 163:297–307PubMed
73.
Guo B, Styles CA, Feng Q, Fink GR (2000) A Saccharomyces gene family involved in invasive growth, cell–cell adhesion, and mating. Proc Natl Acad Sci U S A 97:12158–12163PubMedCentralPubMed
74.
Sheppard DC, Yeaman MR, Welch WH et al (2004) Functional and structural diversity in the Als protein family of Candida albicans. J Biol Chem 279:30480–30489PubMed
75.
76.
77.
Chakrabarti A, Nayak N, Talwar P (1991) In vitro proteinase production by Candida species. Mycopathologia 114:163–168PubMed
78.
79.
Mohan das V, Ballal M (2008) Proteinase and phospholipase activity as virulence factors in Candida species isolated from blood. Rev Iberoam Micol 25(4):208–210PubMed
80.
Kalkanci A, Güzel AB, Khalil II, Aydin M, Ilkit M, Kuştimur S (2012) Yeast vaginitis during pregnancy: susceptibility testing of 13 antifungal drugs and boric acid and the detection of four virulence factors. Med Mycol 50(6):585–593. doi:10.​3109/​13693786.​2012.​662597 PubMed
81.
Ueno K, Matsumoto Y, Uno J et al (2011) Intestinal resident yeast Candida glabrata requires Cyb2p-mediated lactate assimilation to adapt in mouse intestine. PLoS One 6(9):e24759PubMedCentralPubMed
82.
Sikora M, Dabkowska M, Swoboda-Kopec E et al (2011) Differences in proteolytic activity and gene profiles of fungal strains isolated from the total parenteral nutrition patients. Folia Microbiol (Praha) 56(2):143–148. doi:10.​1007/​s12223-011-0023-3
83.
Negri M, Martins M, Henriques M et al (2010) Examination of potential virulence factors of Candida tropicalis clinical isolates from hospitalized patients. Mycophatologia 169:175–182. doi:10.​1007/​s11046-009-9246-0
84.
Luo G, Samaranayake LP (2002) Candida glabrata, an emerging fungal pathogen, exhibits superior relative cell surface hydrophobicity and adhesion to denture acrylic surfaces compared with Candida albicans. APMIS 110:601–610PubMed
85.
Luo G, Samaranayake LP, Cheung BP, Tang G (2004) Reverse transcriptase polymerase chain reaction (RT-PCR) detection of HLP gene expression in Candida glabrata and its possible role in in vitro haemolysin production. APMIS 112:283–290PubMed
86.
Berila N, Hyroššová P, Subík J (2011) Oxidative stress response and virulence factors in Candida glabrata clinical isolates. Folia Microbiol (Praha) 56(2):116–121. doi:10.​1007/​s12223-011-0016-2
87.
88.
89.
Niimi M, Firth NA, Cannon RD (2010) Antifungal drug resistance of oral fungi. Odontology 98(1):15–25PubMed
90.
Akins RA (2005) An update on antifungal targets and mechanisms of resistance in Candida albicans. Med Mycol 43(4):285–318PubMed
91.
Van Bambeke F, Balzi E, Tulkens PM (2000) Antibiotic efflux pumps. Biochem Pharmacol 60(4):457–470PubMed
92.
Wilson D, Thewes S, Zakikhany K et al (2009) Identifying infection-associated genes of Candida albicans in the postgenomic era. FEMS Yeast Res 9:688–700PubMed
93.
Brunke S, Seider K, Almeida RS et al (2010) Candida glabrata tryptophan-based pigment production via the Ehrlich pathway. Mol Microbiol 76:25–47PubMed
94.
Tscherner M, Schwarzmüller T, Kuchler K (2011) Pathogenesis and antifungal drug resistance of the human fungal pathogen Candida glabrata. Pharmaceuticals 4:169–186. doi:10.​3390/​ph4010169
95.
Henry KW, Nickels JT, Edlind TD (2000) Upregulation of ERG genes in Candida species by azoles and other sterol biosynthesis inhibitors. Antimicrob Agents Chemother 44(10):2693–2700PubMedCentralPubMed
96.
Stead DA, Walker J, Holcombe L et al (2009) Impact of the transcriptional regulator, Ace2, on the Candida glabrata secretome. Proteomics 10:212–223
97.
Calcagno AM, Bignell E, Warn P et al (2003) Candida glabrata STE12 is required for wild-type levels of virulence and nitrogen starvation induced filamentation. Mol Microbiol 50:1309–1318PubMed
98.
Ferrari S, Sanguinetti M, De Bernardis F et al (2011) Loss of mitochondrial functions associated with azole resistance in Candida glabrata results in enhanced virulence in mice. Antimicrob Agents Chemother 55:1852–1860PubMedCentralPubMed
99.
Kaur R, Castaño I, Cormack BP (2004) Functional genomic analysis of fluconazole susceptibility in the pathogenic yeast Candida glabrata: roles of calcium signaling and mitochondria. Antimicrob Agents Chemother 48:1600–1613PubMedCentralPubMed
100.
Miyazaki T, Yamauchi S, Inamine T et al (2010) Roles of calcineurin and crz1 in antifungal susceptibility and virulence of Candida glabrata. Antimicrob Agents Chemother 54:1639–1643PubMedCentralPubMed
101.
Bennett JE, Izumikawa K, Marr KA (2004) Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis. Antimicrob Agents Chemother 48:1773–1777PubMedCentralPubMed
102.
103.
Vermitsky JP, Edlind TD (2004) Azole resistance in Candida glabrata: coordinate upregulation of multidrug transporters and evidence for a Pdr1-Like transcription factor. Antimicrob Agents Chemother 48:3773–3781PubMedCentralPubMed
104.
Vale-Silva L, Ischer F, LeibundGut-Landmann S, Sanglard D (2013) Gain-of-function mutations in PDR1, a regulator of antifungal drug resistance in Candida glabrata, control adherence to host cells. Infect Immun 81(5):1709–1720. doi:10.​1128/​IAI.​00074-13 PubMedCentralPubMed
105.
Paul S, Schmidt JA, Moye-Rowley WS (2011) Regulation of the CgPdr1 transcription factor from the pathogen Candida glabrata. Eukaryot Cell 10(2):187–197PubMedCentralPubMed
106.
107.
Chen KH, Miyazaki T, Tsai HF, Bennett JE (2007) The bZip transcription factor Cgap1p is involved in multidrug resistance and required for activation of multidrug transporter gene CgFLR1 in Candida glabrata. Gene 386(1–2):63–72PubMed
108.
Farahyar S, Zaini F, Kordbacheh P et al (2013) Overexpression of aldo-keto-reductase in azole-resistant clinical isolates of Candida glabrata determined by cDNA-AFLP. Daru 21:1PubMedCentralPubMed
109.
Thompson GR 3rd, Wiederhold NP, Vallor AC, Villareal NC, Lewis JS 2nd, Patterson TF (2008) Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection. Antimicrob Agents Chemother 52:3783–3785PubMedCentralPubMed
110.
Pfaller MA, Castanheira M, Lockhart SR, Ahlquist AM, Messer SA, Jones RN (2012) Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J Clin Microbiol 50:1199–1203PubMedCentralPubMed
111.
Arendrup MC, Perlin DS, Jensen RH, Howard SJ, Goodwin J, Hope W (2012) Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations. Antimicrob Agents Chemother 56:2435–2442PubMedCentralPubMed
112.
Shields RK, Nguyen MH, Press EG et al (2012) The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata. Antimicrob Agents Chemother 56:4862–4869PubMedCentralPubMed
113.
Alexander BD, Johnson MD, Pfeiffer CD et al (2013) Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis 56(12):1724–1732PubMed
114.
Vandeputte P, Tronchin G, Larcher G et al (2008) A nonsense mutation in the ERG6 gene leads to reduced susceptibility to polyenes in a clinical isolate of Candida glabrata. Antimicrob Agents Chemother 52:3701–3709PubMedCentralPubMed
115.
Vandeputte P, Tronchin G, Bergès T, Hennequin C, Chabasse D, Bouchara JP (2007) Reduced susceptibility to polyenes associated with a missense mutation in the erg6 gene in a clinical isolate of Candida glabrata with pseudohyphal growth. Antimicrob Agents Chemother 51:982–990PubMedCentralPubMed
116.
Helmerhorst EJ, Venuleo C, Sanglard D, Oppenheim FG (2006) Roles of cellular respiration, CgCDR1, and CgCDR2 in Candida glabrata resistance to histatin 5. Antimicrob Agents Chemother 50:1100–1103PubMedCentralPubMed
117.
Edgerton M, Koshlukova SE (2000) Salivary histatin 5 and its similarities to the other antimicrobial proteins in human saliva. Adv Dent Res 14:16–21PubMed
118.
Helmerhorst EJ, Oppenheim FG (2004) The antifungal mechanisms of antimicrobial proteins. In: Hancock REW, Devine D (eds) Mammalian antimicrobial proteins, 1st edn. Cambridge University Press, Cambridge, pp 245–277
119.
Oppenheim FG (1989) Salivary histidine-rich proteins. In: Tenovuo JO (ed) Human saliva: clinical chemistry and microbiology. CRC Press, Boca Raton, pp 151–160
120.
Oppenheim FG, Xu T, McMillian FM et al (1988) Histatins, a novel family of histidine-rich proteins in human parotid secretion. Isolation, characterization, primary structure, and fungistatic effects on Candida albicans. J Biol Chem 263:7472–7477PubMed
121.
Tsai H, Bobek LA (1998) Human salivary histatins: promising anti-fungal therapeutic agents. Crit Rev Oral Biol Med 9:480–497PubMed
122.
Van Urk H, Voll WSL, Scheffers WA, van Dijken JP (1990) Transient-state analysis of metabolic fluxes in Crabtree-positive and Crabtree-negative yeasts. Appl Environ Microbiol 56:281–287PubMedCentralPubMed
123.
Niimi M, Kamiyama A, Tokunaga M (1988) Respiration of medically important Candida species and Saccharomyces cerevisiae in relation to glucose effect. J Med Vet Mycol 26:195–198PubMed
124.
Shahi P, Moye-Rowley WS (2009) Coordinate control of lipid composition and drug transport activities is required for normal multidrug resistance in fungi. Biochim Biophys Acta 1794:852–859PubMedCentralPubMed
125.
Muller H, Thierry A, Coppée JY et al (2009) Genomic polymorphism in the population of Candida glabrata: Gene copy-number variation and chromosomal translocations. Fungal Genet Biol 46:264–276PubMed
126.
Thierry A, Bouchier C, Dujon B, Richard GF (2008) Megasatellites: a peculiar class of giant minisatellites in genes involved in cell adhesion and pathogenicity in Candida glabrata. Nucleic Acids Res 36(18):5970–5982PubMedCentralPubMed
127.
Barchiesi F, Falconi Di Francesco L, Arzeni D, Caselli F, Gallo D, Scalise G (1999) Electrophoretic karyotyping and triazole susceptibility of Candida glabrata clinical isolates. Eur J Clin Microbiol Infect Dis 18:184–187PubMed
128.
129.
Klempp-Selb B, Rimek D, Kappe R (2000) Karyotyping of Candida albicans and Candida glabrata from patients with Candida sepsis. Mycoses 43:159–163PubMed
130.
Lin CY, Chen YC, Lo HJ, Chen KW, Li SY (2007) Assessment of Candida glabrata strain relatedness by pulsed-field gel electrophoresis and multilocus sequence typing. J Clin Microbiol 45:2452–2459PubMedCentralPubMed
131.
Shin JH, Chae MJ, Song JW et al (2007) Changes in karyotype and azole susceptibility of sequential bloodstream isolates from patients with Candida glabrata candidemia. J Clin Microbiol 45:2385–2391PubMedCentralPubMed
132.
Magee BB, Sanchez MD, Saunders D, Harris D, Berriman M, Magee PT (2008) Extensive chromosome rearrangements distinguish the karyotype of the hypovirulent species Candida dubliniensis from the virulent Candida albicans. Fungal Genet Biol 45:338–350PubMedCentralPubMed
133.
Samaranayake LP (1990) Host factors and oral candidosis. In: Samaranayake LP, MacFarlane TW (eds) Oral candidosis. Wright-Butterworth, London, pp 66–103
134.
Hawser SP, Baillie GS, Douglas LJ (1998) Production of extracellular matrix by Candida albicans biofilms. J Med Microbiol 47(3):253–256PubMed
135.
Chandra J, Mukherjee PK, Leidich SD et al (2001) Antifungal resistance of candidal biofilms formed on denture acrylic in vitro. J Dent Res 80(3):903–908PubMed
136.
Al-Fattani MA, Douglas LJ (2004) Penetration of Candida biofilms by antifungal agents. Antimicrob Agents Chemother 48(9):3291–3297PubMedCentralPubMed
137.
Blankenship JR, Mitchell AP (2006) How to build a biofilm: a fungal perspective. Curr Opin Microbiol 9(6):588–594PubMed
138.
Chandra J, Kuhn DM, Mukherjee PK, Hoyer LL, McCormick T, Ghannoum MA (2001) Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J Bacteriol 183(18):5385–5394PubMedCentralPubMed
139.
Ramage G, Vande Walle K, Wickes BL, López-Ribot JL (2001) Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob Agents Chemother 45(9):2475–2479PubMedCentralPubMed
140.
Hawser S (1996) Adhesion of different Candida spp. to plastic: XTT formazan determinations. J Med Vet Mycol 34(6):407–410PubMed
141.
Mah TFC, O’Toole GA (2001) Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol 9:34–39PubMed
142.
Uppuluri P, Chaturvedi AK, Srinivasan A et al (2010) Dispersion as an important step in the Candida albicans biofilm developmental cycle. PLoS Pathog 6(3):e1000828PubMedCentralPubMed
143.
Perumal P, Mekala S, Chaffin WL (2007) Role for cell density in antifungal drug resistance in Candida albicans biofilms. Antimicrob Agents Chemother 51(7):2454–2463PubMedCentralPubMed
144.
145.
Bandara HM, Lam OL, Watt RM, Jin LJ, Samaranayake LP (2010) Bacterial lipopolysaccharides variably modulate in vitro biofilm formation of Candida species. J Med Microbiol 59(Pt 10):1225–1234. doi:10.​1099/​jmm.​0.​021832-0 PubMed
146.
Halliwell SC, Smith MCA, Muston P, Holland SL, Avery SV (2012) Heterogeneous expression of the virulence-related adhesin Epa1 between individual cells and strains of the pathogen Candida glabrata. Eukaryot Cell 11(2):141–150PubMedCentralPubMed
147.
148.
Cannon RD, Lamping E, Holmes AR et al (2007) Candida albicans drug resistance—another way to cope with stress. Microbiology 153(Pt 10):3211–3217PubMed
149.
Seneviratne CJ, Wang Y, Jin L, Abiko Y, Samaranayake LP (2010) Proteomics of drug resistance in Candida glabrata biofilms. Proteomics 10:1444–1454PubMed
150.
LaFleur MD, Kumamoto CA, Lewis K (2006) Candida albicans biofilms produce antifungal-tolerant persister cells. Antimicrob Agents Chemother 50(11):3839–3846PubMedCentralPubMed
151.
Lewis K (2008) Multidrug tolerance of biofilms and persister cells. Curr Top Microbiol Immunol 322:107–131PubMed
152.
153.
Lafleur MD, Qi Q, Lewis K (2010) Patients with long-term oral carriage harbor high-persister mutants of Candida albicans”. Antimicrob Agents Chemother 54(1):39–44PubMedCentralPubMed
Metadata
Title
Candida glabrata: a review of its features and resistance
Authors
C. F. Rodrigues
S. Silva
M. Henriques
Publication date
01-05-2014
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 5/2014
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-013-2009-3

Other articles of this Issue 5/2014

European Journal of Clinical Microbiology & Infectious Diseases 5/2014 Go to the issue

Article

Laboratory diagnosis of Lyme neuroborreliosis: a comparison of three CSF anti-Borrelia antibody assays

Article

Genetic and phenotypic analysis of Vibrio cholerae non-O1, non-O139 isolated from German and Austrian patients

Article

Comparison of the Kato-Katz method and ether-concentration technique for the diagnosis of soil-transmitted helminth infections in the framework of a randomised controlled trial

Article

Risk factors and pathogens involved in early ventilator-acquired pneumonia in patients with severe subarachnoid hemorrhage

Article

Evaluation of two matrix-assisted laser desorption ionization–time of flight mass spectrometry systems for identification of viridans group streptococci

Article

Feasibility of matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF MS) networking in university hospitals in Brussels
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits